Company Description
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer.
The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID-19; and TRX100 (Tivoxavir marboxil), an endonuclease inhibitor in development for the treatment of pandemic influenza.
It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and rigosertib, which is administered alone or in combination for investigation in various cancers.
It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., and Temple University.
The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024.
Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
| Country | United States |
| Founded | 1998 |
| IPO Date | Jul 25, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Iain Dukes |
Contact Details
Address: 12 Penns Trail Newtown, Pennsylvania 18940 United States | |
| Phone | 267 759 3680 |
| Website | trawspharma.com |
Stock Details
| Ticker Symbol | TRAW |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001130598 |
| CUSIP Number | 68232V884 |
| ISIN Number | US68232V8845 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Iain D. Dukes DPHIL, M.A., Ph.D. | Interim Chief Executive Officer and Executive Chairman |
| Dr. Victor Moyo M.D. | Chief Medical Officer of Oncology |
| Nora E. Brennan | Interim Chief Financial Officer |
| Dr. Nikolay Savchuk Ph.D. | Chief Operating Officer and Director |
| Dr. Robert R. Redfield M.D. | Chief Medical Officer |
| Dr. Charles David Pauza Ph.D. | Chief Scientific Officer of Virology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 30, 2025 | 10-K/A | [Amend] Annual report |
| Apr 18, 2025 | 8-K | Current Report |
| Apr 7, 2025 | 8-K | Current Report |
| Apr 7, 2025 | 424B5 | Filing |
| Mar 31, 2025 | 10-K | Annual Report |
| Mar 31, 2025 | 8-K | Current Report |
| Mar 28, 2025 | 8-K | Current Report |
| Mar 25, 2025 | 8-K | Current Report |
| Mar 24, 2025 | 8-K | Current Report |
| Mar 21, 2025 | 8-K | Current Report |